Tim is a Partner, Head of Research and a co-founding member of Cowen Healthcare Investments. Tim focuses on investments in life science and digital medicine companies that have the potential to meaningfully address serious medical conditions. He is currently a member of the Board of Directors of Anaveon, Lycia Therapeutics, F2G and Autobahn Therapeutics. Tim previously served as a Board Member or Board Observer of Vectiv Bio Holdings AG, Therachon, Precision Biosciences, Livongo Health, Cadent Therapeutics, Cullinan Oncology and Compass Therapeutics. Tim holds a BA in economics from Bowdoin College.
- Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual MeetingJune 5, 2023
- Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual MeetingJune 3, 2023
- Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual MeetingApril 18, 2023